


**Induction of Labor:
Indications, Methods,
Challenges and Outcomes**


Sarah L. Hutto, MD, MPH
Department of Obstetrics, Gynecology and Women's Health



UNIVERSITY OF MINNESOTA
Driven to Discover™

Learning Objectives


- 1) List common indications and contraindications for induction of labor
- 2) Describe methods available for labor induction
- 3) Understand appropriate use of each method of induction
- 4) Discuss challenges faced with labor induction
- 5) Identify outcomes associated with induction of labor
- 6) Comprehend recommendations for induction of labor of specific groups including women with history of previous cesarean section, premature rupture of membranes, post-term pregnancy, diabetes and hypertension




UNIVERSITY OF MINNESOTA
Driven to Discover™

Induction of Labor

- **Definition**
 - The use of techniques for stimulating uterine contractions to accomplish delivery prior to the onset of spontaneous labor
- **Goal**
 - Achieve vaginal delivery within 24 hours and reduce the rate of cesarean delivery without increasing adverse maternal and neonatal outcomes




UNIVERSITY OF MINNESOTA
Driven to Discover™



- ### Medical and Obstetrical Indications for Induction
- Post-term pregnancy
 - PROM
 - Chronic/Gestational Hypertension, Preeclampsia, Eclampsia, HELLP
 - Fetal demise
 - Chorioamnionitis
 - Placental abruption
 - Maternal medical conditions
 - Diabetes, Renal disease, Chronic pulmonary disease, APS
 - Fetal indications
 - Growth restriction, Isoimmunization, Oligohydramnios
- UNIVERSITY OF MINNESOTA
Driven to Discover™

- ### Contraindications for Induction
- Vasa previa
 - Placenta previa
 - Transverse lie
 - Umbilical cord prolapse
 - Active genital herpes infection
 - Invasive cervical cancer
 - Previous classical cesarean delivery
 - Previous myomectomy entering endometrial cavity
 - Prior uterine rupture
 - Category III fetal heart rate tracing
- UNIVERSITY OF MINNESOTA
Driven to Discover™

Elective Induction



UNIVERSITY OF MINNESOTA
Driven to Discover™

Cost of Elective Induction

- Results in over 12,000 excess cesarean deliveries
- Imposes costs to the US medical system of nearly \$100 million per year
- Most costly inductions?
 - Nulliparous women with unfavorable cervix at 39 weeks
 - When favorable, costs are reduced by half!

UNIVERSITY OF MINNESOTA
Driven to Discover™

Once we determine induction is indicated and appropriate, what is the next step?



UNIVERSITY OF MINNESOTA
Driven to Discover™

COUNSEL THE PATIENT!!!

- Discuss indication for induction
- Introduce the agents and methods of labor stimulation
- Acknowledge the possibility of need for repeat induction or cesarean delivery
- Set expectations for length of process



Where to start?

Table 1. Bishop Scoring System

Score	Factor				
	Dilation (cm)	Position of Cervix	Effacement (%)	Station*	Cervical Consistency
0	Closed	Posterior	0-30	-3	Firm
1	1-2	Midposition	40-50	-2	Medium
2	3-4	Anterior	60-70	-1, 0	Soft
3	5-6	—	80	+1, +2	—

*Station reflects a -3 to +3 scale.
Modified from Bishop BH. Pelvic scoring for elective induction. *Obstet Gynecol* 1964;24:267.



Cervical ripening vs. Labor induction

- Unfavorable cervix: Bishops score less than or equal to 6
 - Probability of vaginal delivery is lower if labor is induced
- Favorable cervix: Bishops score greater than 8
 - Probability of vaginal delivery is the same whether labor is spontaneous or induced
- In general: Patient's with an unfavorable cervix will benefit from initiation with cervical ripening



Cervical Ripening

- Ripening Agents
 - Misoprostol (PGE1)
 - Prepidil (PGE2)
 - Cervidil (PGE2)
 - Oxytocin
- Mechanical Methods
 - Single or double balloon catheters
 - Hygroscopic/Osmotic dilators



Misoprostol

- Prostaglandin E1
- Brand name: Cytotec
- FDA approved for treatment and prevention of gastric ulcers
- Off label use for labor induction in women without history of cesarean section



Misoprostol administration




- Available in 100 mcg and 200 mcg tablets
- Route: oral, sublingual, buccal or vaginal
- Typical use: 25 mcg vaginally every 3-6 hours



Outcomes using vaginal misoprostol

- Compared to no treatment/placebo
 - Improved rates of vaginal delivery within 24 hours (RR 0.40; CI 0.22-0.70, 2 trials).
- Compared to other prostaglandins
 - Decreased risk of failure to achieve vaginal delivery within 24 hours (RR 0.78; CI 0.67-0.91, 8 trials)
 - Decreased need for oxytocin augmentation (RR 0.69; CI 0.56-0.8, 10 trials)
- Compared to balloon catheters
 - No statistically significant difference in likelihood of vaginal delivery within 24 hours (RR 1.26, CI 0.94-1.68, 7 trials)
 - No statistically significant difference in cesarean delivery rates (RR 1.01, CI 0.90-1.13, 21 trials)
- Compared to oxytocin
 - Reduced risk of failure to achieve vaginal delivery in 24 hours (RR 0.53, CI 0.33-0.84, 1 trial)
 - Reduced cesarean delivery rate (RR 0.58, CI 0.37-0.90, 5 trials)



Dinoprostone

- Prostaglandin E2
- Brand Names (US):
 - Prepidil: Gel, contains 0.5 mg dinoprostone in 2.5 mL of gel
 - Cervidil: Vaginal insert, contains 10 mg dinoprostone in time release formulation (0.3 mg/h)
- FDA approved for use of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for induction of labor



Dinoprostone administration

- Prepidil
 - May repeat dose every 6-12 hours up to a maximum dose of 1.5 mg (three doses) within 24 hours
- Cervidil
 - Remove/replace every 12 hours



Outcomes using dinoprostone

- Compared to placebo/no treatment
 - Reduced likelihood of vaginal delivery not achieved in 24 hours (RR 0.19, CI 0.14-0.25, 2 trials)
 - Reduced rate of continuation of unfavorable cervix after 12-24 hours (RR 0.46, CI 0.35-0.62, 5 trials)
 - Reduced need for oxytocin augmentation (RR 0.83, C 0.73-0.94, 12 trials)
- Compared to balloon catheters
 - Proportion of women who did not achieve vaginal delivery within 24 hours was not significantly different (RR 1.72, CI 0.90-3.27, 3 studies)




Balloon catheters

- Options
 - Foley catheter #16 inflated with 30-80 mL
 - Cook catheter with intrauterine balloon inflated with 40-80 mL, vaginal balloon inflated with 20-80 mL



Balloon administration




- May place during digital exam or with speculum using a ring forceps or urologic sound
- May leave in place until extruded or for up to 12 hours
- Goal is to have intrauterine balloon distended with saline and retracted so it rests against the internal os




Balloon outcomes

- Compared to prostaglandins
 - Substantial reduction in tachysystole with fetal heart rate changes (RR 0.19, CI 0.08-0.43, 9 trials)
- With or without oxytocin
 - RCT in 2008 showed combined use did not shorten time to delivery, had no effect on likelihood of delivery within 24 hours, and had no effect on vaginal delivery rate
- Single versus Double balloon
 - In 2 comparative trials, there was no clinically important difference in outcomes with use of double versus single balloon catheter (time to delivery and cesarean delivery)
- Single balloon with 30 mL vs. 60 mL
 - Higher proportion of women who received 60 mL achieved delivery within 12 hours, but no difference in median time interval to delivery or proportion of women who achieved delivery within 24 hours
 - The median cervical dilation after balloon expulsion was significantly higher in the 60 mL group (4 versus 3 cm)
- With rupture of membranes
 - No data specifically looking at risk of infection with respect to duration of ruptured membranes before and/or after insertion of a balloon catheter
 - Some practitioners do not place in women with ROM, some remove catheter if membranes rupture at any time after placement, others limit duration to 12 hours if membranes rupture after placement
 - There is NO CONSENSUS ON OPTIMAL MANAGEMENT IN THIS SETTING



 UNIVERSITY OF MINNESOTA
 Driven to Discover™

Oxytocin


- Brand name: Pitocin
- Synthetic analog of oxytocin
- Mechanism of action
 - Stimulates uterine contractions
 - Increases local prostaglandin production, further stimulating uterine contractions
- In general, less successful when used in women with a low Bishop score, and as such, a ripening process should be used prior to administering oxytocin to women with unfavorable cervixes


 UNIVERSITY OF MINNESOTA
 Driven to Discover™

Oxytocin administration




- For IOL, typically given IV
- Low dose and high dose protocols given through infusion pumps
- Goal to have strong contractions every 2-3 minutes, or uterine activity reaches 200-250 Montevideo units
- No benefit in increasing dose when one of these endpoints is achieved


 UNIVERSITY OF MINNESOTA
 Driven to Discover™

Cost of methods

- Misoprostol 25 mcg: \$0.21-0.61
- Cervidil: \$175.00-277.90
- Prepidil: \$150.00-480.24
- Foley catheter: ~\$3.00
- Cook catheter: ~\$41.00
- Pitocin (10u/mL): \$7.19




Hygroscopic/Osmotic Dilators

- Laminaria and Dilapan
- Primarily used during pregnancy termination rather than for pre-induction cervical ripening of term pregnancies
- Concern for potential higher incidence of postpartum maternal and fetal infections compared to prostaglandin analogues




Amniotomy

- Deliberate rupture of the amniotic sac to induce or expedite labor
- Ensure head is well applied to reduce risk of prolapse of cord or fetal part




Amniotomy outcomes

- Amniotomy plus oxytocin versus amniotomy alone
 - Fewer women undelivered at 24 hours in combined group (RR 0.13, CI 0.04-0.41)
 - RCT showed greatest impact on duration of labor is to initiate oxytocin immediately after amniotomy, not delay administration
- Amniotomy plus oxytocin versus oxytocin alone
 - In one RCT, routine early amniotomy in nulliparous labor induction shortened the time to delivery by > 2 hours and increased the proportion of deliveries within 24 hours (RR 0.72, CI 0.59-0.89)



Membrane stripping

- During cervical exam, insertion of finger beyond the cervical os and rotating the finger circumferentially along the lower uterine segment to detach the fetal membranes
- Can be performed in the office in women with a partially dilated cervix who want to hasten onset of spontaneous labor



Membrane stripping outcomes

- Meta-analysis including 22 trials
 - Increased likelihood of spontaneous labor in 48 hours (RR 0.77, CI 0.70-0.84) or delivery within 1 week (RR 0.71, CI 0.65-0.78)
 - Compared to no intervention, reduced frequency of pregnancy continuing beyond 41 weeks (RR 0.59, CI 0.46-0.74) and 42 weeks (RR 0.28, CI 0.15-0.50)
 - Reduced frequency for formal induction compared to no intervention (RR 0.72, CI 0.52-1.00)
 - NNT: 8 women to avoid 1 formal induction
- NO IMPROVEMENT IN MATERNAL OR NEONATAL OUTCOMES



Should we offer routine membrane stripping?

- Important for patient's to understand no maternal or neonatal outcome improvements, solely improved rate of entering spontaneous labor
- Reasonable to offer in well-dated pregnancies greater than or equal to 39 weeks
- GBS infection?
 - No studies have shown a direct contra-indication, but there is no good safety data and so must discuss potential risks and benefits with GBS carriers



Nipple stimulation



- Cochrane meta-analysis
 - Not more useful in women with unfavorable cervix
 - Not more effective than oxytocin
 - Is effective for initiating labor within 72 hours in women with favorable cervix



Other methods

- Glucocorticoids
- Castor Oil
- Hyaluronidase
- Isosorbide mononitrate
- Acupuncture
- Evening primrose oil
- Herbal preparations
- Intercourse
- Exercising



Failed Induction

- No universal standard
- Important to allow adequate time for cervical ripening and development of active labor pattern
 - Decreases potential for cesarean delivery in women still in latent phase of labor
- Once induced women enter active labor, progression is comparable to women with spontaneous active labor or faster



When do we call it?

- Definition offered by NICHD, SMFM and ACOG
 - Cervical ripening with prostaglandins over a period ranging from a single dose to several doses or mechanical methods over 1-2 days prior to oxytocin administration
 - CERVICAL RIPENING IS NOT INCLUDED WHEN CALCULATING THE LENGTH OF INDUCTION OR DIAGNOSING FAILED INDUCTION!!!!
 - Failure to generate regular contractions approximately every 3 minutes and cervical change after at least 24 hours of oxytocin
 - Membranes should be artificially ruptured if safe and feasible
 - After AROM, may consider failed IOL if regular contractions and cervical change do not occur after at least 12 hours of oxytocin administration



The dreaded gray zone

- Active labor (Cervix 6 cm to complete)
 - So, what about 3 to 6 cm? Most data shows ripening agents get us to 3-4 cm
 - Based on retrospective cohort study comparing duration of first stage of labor in induced labor versus spontaneous labor
 - Can take 8 to 10 hours for each centimeter of dilation between 3 and 5 cm (95%ile)
 - Can take 4 to 6 hours for dilation between 5 to 6 cm (95%ile)



Take home message



UNIVERSITY OF MINNESOTA
Driven to Discover™

Special population: TOLAC



- Best method, efficacy and safety of cervical ripening and/or labor induction in these women has not been established!

UNIVERSITY OF MINNESOTA
Driven to Discover™


TOLAC: IOL

- IOL associated with significantly higher risk of unsuccessful TOLAC compared to spontaneous labor
- Women with a history of prior vaginal delivery and a favorable cervix have an increased chance of successful IOL
- Calculators exist to calculate likelihood of successful TOLAC

UNIVERSITY OF MINNESOTA
Driven to Discover™


Uterine rupture and TOLAC IOL

- Systematic review of pooled data from controlled studies of women with prior CS reported the odds of uterine rupture with IOL vs. spontaneous labor OR 6.15 (CI 0.74-51.4)
- One large, well-designed prospective study reported an OR 2.86 (CI 1.75-4.67) and an absolute risk of rupture 1% with IOL versus 0.4% with spontaneous labor
- In a nested case-control study women induced with a favorable cervix had similar risk of rupture as women in spontaneous labor (HR 1.5, CI 0.97-2.36), whereas an unfavorable cervix increased risk of rupture (HR 4.09, CI 1.82-9.17)



IOL for TOLAC

- Misoprostol should NOT be used
- Mixed data regarding other types of prostaglandins, no definitive recommendation made, would not use for now
- Given the lack of compelling data suggesting increased risk with mechanical dilation and transcervical catheters, such interventions MAY be an option for TOLAC candidates with an unfavorable cervix
- Oxytocin augmentation may be used in patients undergoing TOLAC as there are varying outcomes of available studies and there is a small absolute risk reported in those studies
- Amniotomy not contra-indicated and if completed, consider addition of oxytocin



Special Population: PROM

- Patient's should be given adequate time for latent phase of labor to progress
- No evidence that using any type of prostaglandin vaginally increases the risk of infection
 - In one study, only one dose of intravaginal misoprostol was necessary to successful labor induction in 86% if patients
- Largest randomized study found that oxytocin administration reduced the time interval between PROM and delivery as well as frequency of chorioamnionitis, postpartum febrile morbidity and neonatal antibiotic treatments without increasing cesarean deliveries or neonatal infections
- A meta-analysis comparing expectant management versus IOL with prostaglandin or oxytocin showed reduction in risk of chorioamnionitis or endometritis and decreased NICU admissions for neonates in women who underwent IOL



Special Population: Post-term pregnancy

- Late-term (41+0-41+6)
 - Induction can be considered versus expectant management with antenatal testing
- Post-term (42+)
 - Induction is recommended



Special Population: Gestational Diabetes

- GDMA1
 - No early term induction indicated
- GDMA2
 - If well controlled, induce at 40 weeks
 - If poor control, induce at 37-39 weeks




Special Population: Pregestational Diabetes

- Type 1 DM
 - If good control, induce at 39 weeks
 - If poor control, induce at 37-39 weeks
- Type 2 DM
 - If good control, induce at 40 weeks
 - If poor control, induce at 37-39 weeks



Special Population: Gestational Hypertension


- Mild (No Magnesium required)
 - If develop > 39 weeks induce
 - Induce at 37 weeks, can be individualized 37-38+6 weeks
- Severe (Magnesium required)
 - If > 34 weeks induce
 - If < 34 weeks, may expectantly manage in hospital setting



UNIVERSITY OF MINNESOTA
Driven to Discover™

Special Population: Pre-eclampsia


- Without severe features
 - Induce at 37 weeks
- With severe features
 - Induce at 34 weeks, development prior to 34 week, inpatient expectant management option



UNIVERSITY OF MINNESOTA
Driven to Discover™

Special Population: Chronic Hypertension and Superimposed Preeclampsia

- Chronic Hypertension
 - Induce at 38 weeks
- Superimposed preeclampsia
 - Without severe features: Induce at 37 weeks
 - With severe features: Induce at 34 weeks, development prior to 34 weeks, inpatient expectant management option



UNIVERSITY OF MINNESOTA
Driven to Discover™

References

- Induction of Labor. ACOG Practice Bulletin No. 107. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2009;114:386-97.
- Vaginal birth after previous cesarean delivery. Practice Bulletin No. 115. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2010;116:400-03.
- Management of Stillbirth. ACOG Practice Bulletin No. 102. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2009; 113:743-61.
- Martin JA, Hamilton BE, Osterman JK, et al. Births: Final data for 2011. National vital statistics reports; vol 62 no 9. Hyattsville, MD: National Center for Health Statistics, 2013.
- Holmery GJ, Gomezguez AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. *Cochrane Database Syst Rev* 2010; CD000941.
- Austin SC, Sanchez-Ramos L, Adair CD. Labor induction with intravaginal misoprostol compared with the dinoprostone vaginal insert: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2010; 202:804.e1.
- Fox NS, Saltzman DH, Roman AS, et al. Intravaginal misoprostol versus Foley catheter for labour induction: a meta-analysis. *BJOG* 2011; 118:647.
- Heinemann J, Gilen G, Sanchez-Ramos L, Kaunitz AM. Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review. *Am J Obstet Gynecol* 2008; 199:177.
- Perred CE, Henderson JJ, O'Neill MJ, et al. Induction of labour in nulliparous women with an unfavourable cervix: a randomized controlled trial comparing double and single balloon catheters and PGE2 gel. *BJOG* 2009; 116:1443.
- Sahn R, Zaffar N, Nachum Z, et al. Single-balloon compared with double-balloon catheters for induction of labor: a randomized controlled trial. *Obstet Gynecol* 2011; 118:79.
- Levy R, Kaniengser B, Furman B, et al. A randomized trial comparing a 30-mL and an 80-mL Foley catheter balloon for preinduction cervical ripening. *Am J Obstet Gynecol* 2004; 191:1632.
- Delaney S, Shaffer BL, Cheng YW, et al. Labor induction with a Foley balloon inflated to 30 mL compared with 60 mL: a randomized controlled trial. *Obstet Gynecol* 2010; 116:2258.
- Jozwik M, Bismarck KW, Kelly AJ, et al. Mechanical methods for induction of labour. *Cochrane Database Syst Rev* 2012; 3:CD001233.
- Peltier CM, Pocock SB, Sirok DP, et al. Transcervical Foley catheter with and without oxytocin for cervical ripening: a randomized controlled trial. *Obstet Gynecol* 2008; 111:1320.
- Howarth GR, Botha DJ. Amniotomy plus intravenous oxytocin for induction of labour. *Cochrane Database Syst Rev* 2001; CD003250.
- Seo-Oyeme DO, Pisal P, Lawal O, et al. A randomised controlled trial of amniotomy and immediate oxytocin infusion versus amniotomy and delayed oxytocin infusion for induction of labour at term. *Arch Gynecol Obstet* 2009; 279:813.
- Maccones GA, Cahill A, Szabo DM, Odibo AO. The efficacy of early amniotomy in nulliparous labor induction: a randomized controlled trial. *Am J Obstet Gynecol* 2012; 207:403.e1.
- Bollaam M, Stan G, Ison O. Membrane sweeping for induction of labour. *Cochrane Database Syst Rev* 2005; CD000491.



References, cont.

- Kavanagh J, Kelly AJ, Thomas J. Breast stimulation for cervical ripening and induction of labour. *Cochrane Database Syst Rev* 2005; CD003292.
- Spring CV, Berghella V, Westrom KD, et al. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. *Obstet Gynecol* 2012; 120:1181.
- Rouse DJ, Owen J, Haultz JC. Criteria for failed labor induction: prospective evaluation of a standardized protocol. *Obstet Gynecol* 2000; 96:871.
- Rouse DJ, Weiner SJ, Blom SL, et al. Failed labor induction: toward an objective diagnosis. *Obstet Gynecol* 2011; 117:287.
- Beckmann M. Predicting a failed induction. *Aust N Z J Obstet Gynaecol* 2007; 47:394.
- Harpel LM, Caughey AB, Odibo AO, et al. Normal progress of induced labor. *Obstet Gynecol* 2012; 119:1113.
- Jozwik M, Doshi JM. Methods of term labour induction for women with a previous caesarean section. *Cochrane Database Syst Rev* 2013; 3:CD009792.
- Doshi JM, Caughey AB. Elective repeat cesarean section versus induction of labour for women with a previous caesarean birth. *Cochrane Database Syst Rev* 2006; CD004906.
- McDonagh MS, Osterweil P, Gulse JM. The benefits and risks of inducing labour in patients with prior cesarean delivery: a systematic review. *BJOG* 2005; 112:1007.
- Landon MB, Haultz JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. *N Engl J Med* 2004; 351:2581.
- Harpel LM, Cahill AG, Blosbaugh S, et al. Association of induction of labor and uterine rupture in women attempting vaginal birth after cesarean: a survival analysis. *Am J Obstet Gynecol* 2012; 206:51.e1.



Questions?